Skip to main content
Premium Trial:

Request an Annual Quote

Luc Missorten, Roch Doliveux, Robert Dubé, Patrick Oubre, Gretchen Barron, Tamara Goetz, Gov. Jon Huntsman Jr., Gregory Jones

UCB Financial Officer to Leave Company
Luc Missorten will leave his position as executive vice president and chief financial officer of UCB on Sept. 1 “to pursue new opportunities,” the Belgian-owned biopharmaceutical company announced, adding that his successor will be named before he leaves his post.
Missorten joined UCB in February 2004 as general manager of UCB Pharma Spain, and was named chief financial officer nine months later. Before joining UCB, Missorten served as chief financial officer of Belgian-owned Interbrew (now InBev) and started his career at Citibank. He is also a member of the board of directors and chairman of the audit committee of the Vandemoortele Group.
“Luc built and led a high performing team of finance professionals. He was also instrumental in the integration of Celltech and the acquisition of Schwarz Pharma. We thank him for his important contribution to the transformation of UCB and wish him every success in his new endeavors," UCB’s CEO Roch Doliveux said in a press release announcing Missorten’s departure.

Montreal’s Biotech City Names New President/CEO
Robert Dubé has been named new president and CEO of the City of Biotechnology and Human Health of Metropolitan Montreal. Dubé has been Biotech City’s interim president and CEO since January, when he succeeded Pierre Bélanger, in addition to heading the Laval Technopole, which promotes economic development in the city of Laval, since September 2006.
Dubé supervised the start-up of two biotech companies from 2003 to 2006 as the head of VAL-CHUM, the organization formed to oversee commercialization of the research of the roughly 200 researchers of the Centre Hospitalier de l'Université de Montréal.
Anchored by the Laval Science and High Technology Park, Biotech City includes INRS-Armand Frappier Institute, a specialized hospital, clinical and pre-clinical research centers; the National Center for Experimental Biology, a business incubator, the Biotechnology Development Center, and 35 biotech, biopharmaceutical and human health companies ranging from startups to corporate giants.

Utah Economic Development Office Names New Science Adviser
Tamara Goetz has been named Utah science adviser by Gov. Jon Huntsman Jr.’s Office of Economic Development. She succeeds Gregory Jones, who had held the position since 2005.
Goetz worked as director of Salt Lake Community College's biotechnology program, where she helped to create a one-year high school biotechnology program. She also directed the nonprofit company InnovaBio, a student-led company that assists high school and college students with internship opportunities for life science companies.
Goetz also worked with the US Department of Labor's Workforce Innovation in Regional Economic Development initiative, which supports education and training for life sciences in Utah. She served on the Governor's State Advisory Council for science and technology as well as on the board of directors for the Leonardo, a science and culture center set to open 2009 in Salt Lake City.
Goetz was named to Utah Business magazine’s "40 Under 40 Rising Stars" and "30 Women to Watch" lists.

Two Project Managers Rejoin Newton, Mass., Construction Management Firm
Patrick Oubre and Gretchen Barron have rejoined Diversified Project Management. They will return to project manager positions with the Newton, Mass.-based construction management, facilities and move-planning firm.
Before relocating to a Texas position in 2005, Oubre managed the construction of a new 80,000-square-foot office for New York Life, as well as the relocation of over 1,250 people at CVS headquarters in Rhode Island and 2,200 people at the Staples headquarters in Framingham, Mass.
Gretchen oversaw the construction of several projects for the former Fleet Bank, now part of Bank of America, as well as headquarters projects for for Middlesex Savings Bank and EM4 Photonics.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.